ALT - Altimmune, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.5800
+0.1000 (+4.03%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.4800
Open2.4600
Bid2.5500 x 1000
Ask2.6800 x 800
Day's Range2.4400 - 2.6200
52 Week Range1.7000 - 36.2500
Volume355,551
Avg. Volume857,068
Market Cap33.868M
Beta (3Y Monthly)2.34
PE Ratio (TTM)N/A
EPS (TTM)-7.9840
Earnings DateAug 8, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2017-01-20
1y Target Est10.00
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    Altimmune Appoints Will Brown as Chief Financial Officer

    Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced it has appointed Will Brown as Chief Financial Officer. Mr. Brown has been serving as the Acting Chief Financial Officer since May 2018. “Will has proven to be a valuable member of our senior leadership team since he stepped into the CFO role over a year ago,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer.

  • GlobeNewswire5 days ago

    Altimmune Announces Successful Pre-IND Meeting with FDA

    Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced that it successfully completed a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding its Phase 2 trial design and manufacturing plans for HepTcell. The FDA did not object to the planned study design and patient populations, as well as plans for manufacturing and product testing, and did not recommend any additional studies in preparation for an IND submission and initiation of Phase 2 trials. Altimmune intends to conduct a Phase 2 study in the United States and the pre-IND meeting was held to obtain feedback from the FDA on our intended development path.

  • GlobeNewswire10 days ago

    Altimmune Announces Important Additions to its Patent Portfolio for HepTcell and ALT-702 Programs

    Altimmune, Inc. (ALT), a clinical-stage biotechnology company, today announced that it has received additional patent protection for its HepTcell and ALT-702 programs in the United States. “We are pleased to strengthen our intellectual property protection with the additional patents covering our development candidates, HepTcell and ALT-702,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer. For HepTcell, the Company has been granted U.S. Patent No. 10,300,132 entitled “Vaccines Against Hepatitis B Virus.” The patent, which expires in 2035 accounting for 515 days of patent term adjustment, provides important additional IP protection for the HepTcell clinical development program, an immunotherapeutic being developed for patients chronically infected with the hepatitis B virus (“HBV”).

  • GlobeNewswirelast month

    Altimmune Announces First Quarter 2019 Financial Results and Provides a Business Update

    GAITHERSBURG, Md., May 14, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial results for the first quarter ended.

  • GlobeNewswirelast month

    Altimmune to Announce First Quarter 2019 Financial Results on May 15

    GAITHERSBURG, Md., May 08, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the.

  • GlobeNewswire2 months ago

    Altimmune To Present NasoVAX Phase 2 Data at the World Vaccine Congress in Washington, D.C.

    Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced an oral presentation at the World Vaccine Congress being held in Washington D.C. on April 14-17, 2019. The presentation will take place on April 16, 2019 at the Renaissance Washington, DC Downtown Hotel at 12:55pm Eastern Time. Dr. Sybil Tasker, Chief Medical Officer of Altimmune, will present data from the Company’s Phase 2 study and the recently completed Phase 2 extension study for NasoVAX.

  • ACCESSWIRE2 months ago

    Altimmune, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 2, 2019 / Altimmune, Inc. (NASDAQ: ALT ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on April 2, 2019 at 8:30:00 AM Eastern ...

  • GlobeNewswire2 months ago

    Altimmune Announces Financial Results for the Year Ended December 31, 2018 and Provides Corporate Update

    GAITHERSBURG, Md., April 01, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial results for the year ended December.

  • GlobeNewswire3 months ago

    Altimmune to Announce Year End 2018 Financial Results on April 2

    GAITHERSBURG, Md., March 21, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the.

  • Altimmune News: ALT Stock Skyrockets on Positive Flu Vaccine Data
    InvestorPlace3 months ago

    Altimmune News: ALT Stock Skyrockets on Positive Flu Vaccine Data

    Altimmune news concerning the results from a Phase 2 extension study of the company's NasoVAX has ALT stock heading higher today.Source: Shutterstock Altimmune (NASDAQ:ALT) says that it saw strong results from an extension to the study that has it checking in on patients one year after its completion. This includes 100% of patients that returned for the study extension still being seroprotected.The Altimmune news about its intranasal influenza vaccine candidate NasoVAX notes that patients in the extension were also saw a seroconversion rate that was unchanged from last year. It is also worth noting that these patients were from the highest dosage level of the study.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"We are excited about the continued positive NasoVAX results and believe that if approved, NasoVAX has the potential to capture a significant portion of the global flu vaccine market," Vipin Garg, Ph.D., President and CEO of Altimmune, said in a statement. "Based on the continued positive data, we are seeking development and commercialization partnerships for our NasoVAX program. This will allow us to focus on our strategy of building a pipeline of multiple early to mid-stage assets." * Top 7 Service Sector Stocks That Will Pay You to Own Them The original study from Altimmune about using NasoVAX as an influenza vaccine had 13 people receiving the highest dosage of the vaccine. All 13 were invited to return for the extension, but only eight chose to do so.ALT stock was up 15% as of noon Tuesday and is up 11% since the start of the year. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Financial Stocks to Invest In Today * 7 Single-Digit P/E Stocks With Massive Upside * 5 Chip Stocks on the Rise As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Altimmune News: ALT Stock Skyrockets on Positive Flu Vaccine Data appeared first on InvestorPlace.

  • MarketWatch3 months ago

    Altimmune's stock soars on heavy volume after positive trial data of flu vaccine candidate

    Shares of Altimmune Inc. soared 36% in active premarket trade Tuesday, after the immunotherapeutics company reported "additional positive data" from its flu treatment and said it was seeking development and commercialization partnerships. Volume swelled to more than 1.5 million shares, compared with the full-day average of about 1.7 million shares. The company said a phase 2 extension study of its NasoVAX intranasal influenza vaccine candidate showed that 100% of the evaluated subjects remained seroprotected, and the rate was unchanged more than a year after vaccination. "Based on the continued positive data, we are seeking development and commercialization partnerships for our NasoVAX program," said Chief Executive Vipin Garg. "This will allow us to focus on our strategy of building a pipeline of multiple early to mid-stage assets. We are currently engaged in a rigorous acquisition review process focused on novel immunotherapeutic approaches for cancer, including immunostimulants and oncolytic viruses, and innovative product candidates for liver diseases." The stock has rallied 40.3% year to date through Monday, but has plunged 94% over the past 12 months, while the S&P 500 has climbed 13% the past three months and gained 4.4% the past year.

  • GlobeNewswire3 months ago

    Altimmune Announces Positive Results from NasoVAX Extension Study

    Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced additional positive data from a Phase 2 extension study of its NasoVAX intranasal influenza vaccine candidate. Data from this study demonstrated that 100% of the evaluated subjects remained seroprotected, and the seroconversion rate was unchanged more than one year after vaccination. Subjects from the highest dose group of the study were invited to return as part of a study extension to evaluate the duration of immunity 1-year post-vaccination.

  • GlobeNewswire3 months ago

    Altimmune to Participate at 31st Annual ROTH Conference

    GAITHERSBURG, Md., March 14, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, announced today that Vipin K. Garg, Ph.D., President and Chief.

  • GlobeNewswire3 months ago

    Altimmune Announces Closing of $14 Million Registered Direct Offering

    Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced the closing of the previously announced registered direct offering of common units and pre-funded units receiving gross proceeds of $14 million. On March 8, 2019, the Company disclosed approximately $34.4 million in cash, cash equivalents and restricted cash as of December 31, 2018. Altimmune intends to use the cash on hand together with the net proceeds of approximately $12.7 million from this offering for the continued advancement and development activities for its product pipeline, strategic growth opportunities (including potential acquisitions and/or licensing transactions), and general working capital purposes.

  • GlobeNewswire3 months ago

    Altimmune Announces $14 million Registered Direct Offering

    Each common unit is being sold at a public offering price of $3.21 and consists of one share of common stock and 0.70 of a warrant to purchase one share of common stock at an exercise price of $3.21. Each pre-funded unit is being sold at a public offering price of $3.20 and consists of a pre-funded warrant to purchase one share of common stock at an exercise price of $0.01 per share and 0.70 of a warrant to purchase one share of common stock at an exercise price of $3.21.

  • GlobeNewswire5 months ago

    Altimmune Announces Presentation of HepTcell Phase 1 Results at The International Liver Congress™ in Vienna, Austria

    Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced results of its recently completed HepTcell Phase 1 clinical trial will be presented on April 12, 2019 at The International Liver Congress sponsored by The European Association for the Study of the Liver (EASL) being held in Vienna, Austria April 10-14, 2019. As previously announced, this study met its primary endpoint of safety and showed that HepTcell treatment was associated with increased HBV-specific cellular immune responses.

  • ACCESSWIRE6 months ago

    Today's Research Reports on Trending Tickers: Sage Therapeutics and Altimmune

    NEW YORK, NY / ACCESSWIRE / December 14, 2018 / U.S. markets finished modestly higher on Thursday as investors continue to worry about trade tensions between the U.S. and China. The Dow Jones Industrial ...

  • GlobeNewswire6 months ago

    Altimmune Announces Clinical Program Updates and Plans for Pipeline Expansion

    Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced updates to its clinical programs and plans to further expand its pipeline. As previously announced in September 2018, a monovalent version of NasoVAX, Altimmune's intranasally administered influenza vaccine candidate, elicited statistically significant mucosal antibody responses not seen with the commercially available injectable vaccine Fluzone®, and a nearly 6-fold higher median cellular immune response compared to Fluzone. In addition, the NasoVAX hemagglutination inhibition (HAI) antibody response was stable over the six-month follow-up period, while antibody titers elicited by Fluzone fell over 50% over the same period. The Company is now conducting an extension study for previous Phase 2a study participants to measure further durability of HAI responses one year after vaccination and will be evaluating other clinical measures of NasoVAX immunogenicity.

  • GlobeNewswire6 months ago

    Altimmune Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, granted equity awards on November 30, 2018, that were previously approved by the Compensation Committee of its Board of Directors under Altimmune’s 2018 Inducement Grant Plan, as a material inducement to the employment of Dr. Vipin K. Garg, who commenced employment as Altimmune’s President and Chief Executive Officer on November 30, 2018. Dr. Garg received non-qualified stock options to purchase 211,486 shares of Altimmune’s common stock and a grant of 322,907 restricted shares of Altimmune’s common stock. The stock options have an exercise price of $3.59 per share, which is equal to the closing price of Altimmune’s common stock on November 30, 2018.

  • GlobeNewswire7 months ago

    Altimmune Appoints Vipin K. Garg, Ph.D. as its New President and Chief Executive Officer

    Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced the appointment of Vipin K. Garg, Ph.D. as its President and Chief Executive Officer succeeding Bill Enright, current President and Chief Executive Officer, effective November 30. “Vipin was chosen in a very competitive selection process and we are very excited to have him join Altimmune as President and CEO,” said Mitch Sayare, Chairman of the Board of Altimmune. “His extensive experience and success in building, managing, and financing private and public biotech companies makes him an extraordinary fit for Altimmune.

  • ACCESSWIRE7 months ago

    Today's Research Reports on Trending Tickers: Altimmune and Johnson & Johnson

    NEW YORK, NY / ACCESSWIRE / November 23, 2018 / It was an eventful day of trading for Altimmune which saw gains of almost 10% despite any significant news. Shares of Johnson & Johnson were dragging lower after a U.S. appeals court refused to stop generic versions of its prostate-cancer drug Zytiga from entering the market. Altimmune, Inc. shares closed up nearly 10% on about 3.9 million shares traded on Wednesday.

  • GlobeNewswire7 months ago

    Altimmune Announces Third Quarter 2018 Financial Results and Provides Corporate Update

    GAITHERSBURG, Md., Nov. 13, 2018 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial results for the three and nine months.

  • Gaithersburg biotech CEO to step down
    American City Business Journals8 months ago

    Gaithersburg biotech CEO to step down

    The chief executive will stay in his role, and on the board, until his successor is appointed or early next year, whichever comes first.

  • ACCESSWIRE8 months ago

    Today’s Research Reports on Stocks to Watch: Altimmune and MannKind

    NEW YORK, NY / ACCESSWIRE / October 17, 2018 / Altimmune and MannKind were two biotech stocks flying higher in Tuesday’s session. Altimmune didn’t have any particular news but MannKind announced along ...